I Trephine biopsy o f t e t r a c y c l i n e l a b e l e d bone, p a r a t h y r o i d
hormone l e v e l s and bone densitometry u s i n g photon absorpt i o m e t r y were accomplished i n a 14-year-old g i r l w i t h 45,X karyotype who a l s o has a craniopharyngioma. A t t h e t i m e o f t h e i n i t i a l s t u d i e s , she was t a k i n g replacement h y d r o c o r t isone, 10mg. every morning and 5mg. a t n i g h t and 150mcg. o f Thyroxine d a i l y . The c e l l and t i s s u e l e v e l dynamics o f bone r e m o d e l l i n g were e l e v a t e d and s l i g h t l y above normal compatible w i t h h i g h t u r n o v e r bone. I n r e t r o s p e c t t h i s may have been r e l a t e d t o t h e s l i g h t l y h i g h t h y r o x i n e replacement dose.
Fol lowing e i g h t months o f growth hormone treatment, t h e dynamics showed f u r t h e r i n c r e a s e i n bone a c t i v i t y a t b o t h t h e haversian and e n d o s t e a l -c o r t i c a l surfaces. The t h y r o x i n e replacement remained constant. She grew t h r e e inches, whereas she had p r e v i o u s l y o n l y grown 4 i n c h p e r y e a r . The parat h y r o i d hormone l e v e l s d i d n o t change s i g n i f i c a n t l y . The bone densitometry was 7 standard d e v i a t i o n s below normal f o r age and sex and d i d n o t change s i g n i f i c a n t l y w i t h treatment. Calcium (Ca) disorders and therapeutic effectiveness can be assessed by measurements of bone dynamics using stable tracer me thods. A pulse of IV Ca-46 is followed by a 9-15 day continuous feeding of Ca-48. Ca isotopic abundances in serum, urine, and feces are determined by thermoionization mass spectrometry (0.51 precision). Kinetic parameters (mg/kg/d) are calculated by nonlinear, weighted least squares analysis and growth is compensate for by using expanding pool sizes. Two infants (Inf.) had Ca turnover rates 12 times that of a control adult (Ad); bone Ca deposition (vo+) and resorption (v ) were determined with 2 to 5% precision. Two infants with osfeogenesis imperfecta (01) we1 studied before (B) and while taking ascorbic acid ( C ) . S p e c i f i c 1251 i n s u l i n b i n d i n q t o c i r c u l a t i n q monocytes was s t u d i e d i n a group o f 13 p a t i e n & w i t h CF, 4 o f whom were i n s u l i dependent. Nine u n t r e a t e d p a t i e n t s had m i l d carbohydrate i n t o 1 -erance i n response t o o r a l glucose as compared t o c o n t r o l s (201f 26mg/dl vs.103f6 MfSEm at 2h; 144f26 vs.92*5 at 3 h ) . The peak i n s u l i n response was delayed t o 2 hours i n CF and lower than t h e one hour peak o f normals (44mIU/ml vs.66mIU/ml). C a l c u l a t e d i ns u l inogenic index, I 1 (ZAinsul in/ZAglucose) was lower f o r CF t h a c o n t r o l s (0.21f0.05 vs.D.37fD.04 p<0.01), i n d i c a t i n g enhanced i n s u l i n s e n s i t i v i t y . Scatchard a n a l y s i s o f i n s u l i n b i n d i n g r evealed a marked increase i n r e c e p t o r s i t e s i n u n t r e a t e d CF pat i e n t s as compared t o c o n t r o l s ; 44,000 s i t e s / c e l l vs. 25,000 s i t e s / c e l l . S p e c i f i c i n s u l i n b l n d i n g a t t r a c e r c o n c e n t r a t i o n s (0.3nglml) was lower i n CF 3.14% vs.5.14%, and t h e c a l c u l a t e d a f f i n i t y c o n s t a n t f o r b i n d i n g (Ke) was reduced, 0 . 8~1 0 8 X-1 vs.
. 5~1 0 8 M-1. I n s u l i n t r e a t e d p a t i e n t s d i d n o t have lower recept o r numbers o r a l t e r e d a f f i n i t y as compared t o t h e untreated. Thus 1 ) i n CF diminished i n s u l i n s e c r e t i o n i s associated w i t h an increased number o f r e c e p t o r s i t e s ) increased b i n d i n g s i t e s would e x p l a i n s e n s i t i v i t y t o endogenous i n s u l i n , as demonstrated
by t h e decreased I 1 as w e l l as t o exogenous i n s u l i n ( r e p o r t e d by others) 3) t h e consequences o f t h e s u b s t a n t i a l increase i n recept o r number may be o f f s e t somewhat by reduced r e c e p t o r a f f i n i t y . 
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Our previous observation that ZnSOq, added in vitro, both stimulated and stabilized residual leukocyte acidic a-mannosidase activity in two patients (Arch. Neurol. 34, 45, 1977) prompted a therapeutic trial of the metal. Oral ZnSOq in doses ranging from 13-45 mg/kg over a 12-week period raised serum Zn levels to a maximum of twice normal. Average leukocyte acid a-mannosidase activity during the treatment period ranged from 2-5% of control values, showing no significant difference from baseline levels. No treatment related change occurred in the 11 band thin layer chromatographic profile of mannose containing neutral oligosaccharides excreted in a 24-hour urine. Because Zn is known to have a high affinity for tissue uptake, 1 ml containing 10 mg ZnSO4 was injected into the gingiva of patient 1, which had become hyperplastic with PAS-positive storage material A control site was injected with an equal volume of saline. Biopsies before and one month after the injections showed no change in the ultrastructural characteristics of membrane bound cytoplasmic vacuoles. The Zn injected tissue had a moderately increased amount of collagenous stroma, which was not seen in either the saline or pre-injection controls. This may reflect a positive effect on wound healing. Otherwise, ZnSOq does not appear to have specific therapeutic efficacy in ameliorating storage material in mannosidosis under the above conditions. 
